Please login to the form below

Not currently logged in
Email:
Password:

Merz

This page shows the latest Merz news and features for those working in and with pharma, biotech and healthcare.

Merz pulls out of race for Obagi Medical

Merz pulls out of race for Obagi Medical

Leaves Valeant open to complete takeover. Merz Pharma has elected not to raise its $385m offer for dermatology specialist Obagi Medical Products, clearing the way for a takeover by rival Valeant ... Obagi was an opportunity worth pursuing given its

Latest news

  • Battle lines drawn as Valeant ups Obagi bid Battle lines drawn as Valeant ups Obagi bid

    Hits back against Merz offer. Valeant Pharmaceuticals has responded to a rival bid for dermatology specialist Obagi Medical Products from Merz with a higher offer of its own. ... At the time of writing Merz had not issued a response to the new bid.

  • Merz offers $385m to trump Valeant's bid for Obagi Merz offers $385m to trump Valeant's bid for Obagi

    Merz Pharma's $22-per-share bid values Obagi at around $385m, a premium to Valeant's $19.75-a-share offer last month which was equivalent to around $360m. ... Our proposal is clearly superior to the Valeant transaction," said Merz in a letter to Obagi's

  • Allergan gets US approval for Botox in overactive bladder Allergan gets US approval for Botox in overactive bladder

    The drug remains the dominant force in its category despite competition from rival products Dysport (abobotulinumtoxinA) from Ipsen, Merz' Xeomin (incobotulinumtoxinA) and Solstice Neurosciences' Myobloc (rimabotulinumtoxinB), with Allergan claiming

  • Allergan and Cephalon breach ABPI code

    Allergan was found to be in breach of clauses 2, 9.1 and 25 after Merz Pharma alleged that during a presentation, Allergan implied that its Botox/Vistabel was more potent ... than Merz's Xeomin/Bocouture.

  • Slim pickings

    Type 2 diabetes mellitus . Japan. Polidocanol  . Asclera (Merz Aesthetics). Varicose veins .

More from news
Approximately 3 fully matching, plus 17 partially matching documents found.

Latest appointments

  • Ashfield UK makes two new business development appointments Ashfield UK makes two new business development appointments

    Tweedale joins Ashfield after 11 years at Merz Pharma where more recently he served as sales and marketing manager.

  • Bartenbach adds to healthcare management team Bartenbach adds to healthcare management team

    Anja Treiber has worked with CSL Behring, Novo Nordisk, Fresenius Kabi and Merz Pharma. ... In the last two years, Treiber has focused on international pharma clients including CSL Behring, Novo Nordisk, Fresenius Kabi and Merz Pharma.

  • New VP for Merz North America New VP for Merz North America

    Gregory Bass to lead market access and reimbursement strategy. Healthcare company Merz Pharma has appointed Gregory Bass vice president, managed markets. ... Bass will be responsible for developing Merz's North American market access and reimbursement

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Frontera Group Frontera Group

    Medskin Solutions . Menarini Farmaceutica Internazionale . Merck. Merz Pharmaceuticals. Mitsubishi Pharma Europe.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics